Viewing Study NCT00003206



Ignite Creation Date: 2024-05-05 @ 9:42 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00003206
Status: COMPLETED
Last Update Posted: 2023-06-15
First Post: 1999-11-01

Brief Title: Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
Sponsor: Eastern Cooperative Oncology Group
Organization: Eastern Cooperative Oncology Group

Study Overview

Official Title: A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
Status: COMPLETED
Status Verified Date: 2023-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients with locally recurrent or metastatic nasopharyngeal cancer
Detailed Description: OBJECTIVES I Estimate the response and toxicity of carboplatin in combination with paclitaxel in patients with locally recurrent or metastatic nasopharyngeal carcinoma

OUTLINE Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes This cycle is repeated every 3 weeks Patients may receive 6-8 cycles of therapy in the absence of toxicity and disease progression Patients are followed every 3 months for the first 2 years every 6 months for the next 3 years and yearly thereafter

PROJECTED ACCRUAL 30 eligible patients will be accrued in approximately 18 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
E-2397 None None None